Firstly, the predicted diffEnhancers were associated with TF motifs, and for both two cancer type, all 13 drugs’ diffEnhancers were linked with at least one TF motif, and some even had two thousand TF motifs, such as drug trichostatin related enhancer: chr17:48538779–48607552 in prostate cancer (Supplementary Figs. 6B, D), implying the potential regulatory role of these diffEnhancers. Here, TF is linked to prostate carcinoma.